Technical Analysis for GLYC - GlycoMimetics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| See historical GLYC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 15 | NR7 | Range Contraction | 2.48% |
| Jan 15 | Wide Bands | Range Expansion | 2.48% |
| Jan 15 | Overbought Stochastic | Strength | 2.48% |
| Jan 14 | Weak + Overbought | Other | 5.50% |
| Jan 14 | Wide Bands | Range Expansion | 5.50% |
| Jan 14 | Overbought Stochastic | Strength | 5.50% |
| Jan 11 | Stochastic Sell Signal | Bearish | 0.56% |
| Jan 11 | NR7 | Range Contraction | 0.56% |
| Jan 11 | Weak + Overbought | Other | 0.56% |
| Jan 11 | Wide Bands | Range Expansion | 0.56% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-02
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more GLYC news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 26.05 |
| 52 Week Low | 8.29 |
| Average Volume | 332,741 |
| 200-Day Moving Average | 14.5834 |
| 50-Day Moving Average | 11.1162 |
| 20-Day Moving Average | 9.9415 |
| 10-Day Moving Average | 10.524 |
| Average True Range | 0.6786 |
| ADX | 18.63 |
| +DI | 17.1451 |
| -DI | 19.18 |
| Chandelier Exit (Long, 3 ATRs ) | 9.1542 |
| Chandelier Exit (Short, 3 ATRs ) | 10.325799999999999 |
| Upper Bollinger Band | 11.4512 |
| Lower Bollinger Band | 8.4318 |
| Percent B (%b) | 0.68 |
| BandWidth | 30.371674 |
| MACD Line | -0.079 |
| MACD Signal Line | -0.2535 |
| MACD Histogram | 0.1745 |
| Fundamentals | Value |
|---|---|
| Market Cap | 342.94 Million |
| Num Shares | 32.7 Million |
| EPS | -1.34 |
| Price-to-Earnings (P/E) Ratio | -7.82 |
| Price-to-Sales | 18873.21 |
| Price-to-Book | 3.02 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.13 | ||||
| Resistance 3 (R3) | 11.07 | 10.81 | 11.02 | ||
| Resistance 2 (R2) | 10.81 | 10.64 | 10.83 | 10.98 | |
| Resistance 1 (R1) | 10.64 | 10.54 | 10.73 | 10.70 | 10.95 |
| Pivot Point | 10.38 | 10.38 | 10.42 | 10.40 | 10.38 |
| Support 1 (S1) | 10.21 | 10.21 | 10.30 | 10.27 | 10.01 |
| Support 2 (S2) | 9.95 | 10.11 | 9.97 | 9.98 | |
| Support 3 (S3) | 9.78 | 9.95 | 9.94 | ||
| Support 4 (S4) | 9.84 |
